Although this percentage of TP53 mutations is higher than that found in newly diagnosed patients,4 it is consistent with previous studies incorporating genomic profiling in cohorts of patients with MDS or AML undergoing allo‐SCT,13, 24 The median follow‐up period was 18 months. Here, TP53 is linked to acute myeloid leukemia.